CDKN2A and cancer: Consistent with the ATR-LSS axis promoting mTORC1 activity via cholesterol in p16 knockdown cancer cells, knockdown or inhibition of either ATR or LSS decreased mTORC1 activity, and these effects were rescued by supplementation with either lanosterol or cholesterol (Fig. 4A–H).